Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Interest Expenses (2016 - 2026)

Perspective Therapeutics' Interest Expenses history spans 11 years, with the latest figure at $105000.0 for Q1 2026.

  • On a quarterly basis, Interest Expenses fell 17.97% to $105000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $353000.0, a 140.14% increase, with the full-year FY2025 number at $376000.0, up 683.33% from a year prior.
  • Interest Expenses hit $105000.0 in Q1 2026 for Perspective Therapeutics, up from $64000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for CATX hit a ceiling of $128000.0 in Q1 2025 and a floor of -$73000.0 in Q4 2024.
  • Historically, Interest Expenses has averaged $47000.0 across 4 years, with a median of $29000.0 in 2024.
  • Biggest five-year swings in Interest Expenses: tumbled 404.17% in 2024 and later skyrocketed 417.39% in 2025.
  • Tracing CATX's Interest Expenses over 4 years: stood at $24000.0 in 2023, then tumbled by 404.17% to -$73000.0 in 2024, then soared by 187.67% to $64000.0 in 2025, then soared by 64.06% to $105000.0 in 2026.
  • Business Quant data shows Interest Expenses for CATX at $105000.0 in Q1 2026, $64000.0 in Q4 2025, and $65000.0 in Q3 2025.